EpilepsyGTx is a biotechnology company based in the UK, spun out from UCL. The company specializes in developing innovative gene therapies to treat refractory epilepsy, a severe neurological condition resistant to standard treatments. Its lead candidate, EPY201, is an experimental gene therapy designed to treat focal refractory epilepsy. It employs an AAV9 viral vector to deliver a modified Kv1.1 potassium channel to the brain. The therapy is administered directly into the seizure focus through a precise technique called intraparenchymal delivery. This approach aims to address the underlying neurological dysfunctions contributing to epilepsy.
Location: United Kingdom
Total raised: $43M
Investors 1
| Date | Name | Website |
| 23.12.2024 | Health Tec... | hthvc.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 12.12.2025 | Series A | $33M | XGEN VENTU... |
| 24.06.2024 | Seed | $10M | - |
Mentions in press and media 11
| Date | Title | Description |
| 17.02.2026 | Irish Biotech Aerska Secures $39M for Brain Shuttle RNA Medicines | Aerska, an Irish biotech firm, secured a $39 million Series A funding round. This significant investment will propel its proprietary brain shuttle technology. The platform targets challenging neurological diseases. It delivers RNA medicines... |
| 16.02.2026 | Platform designed to cut cell and gene therapy production costs attracts €6.9 million for UK startup Tozaro | Tozaro, a Bedford-based company whose ‘Smart Polymer’ technology looks to significantly reduce the cost of life-saving cell and gene therapies, has completed a €6.9 million (£6 million) funding round. The round was led by Mercia Ventures, i... |
| 10.02.2026 | Irish BioTech startup Aerska raises €32 million to “enable our loved ones to live longer” | Dublin’s Aerska, a BioTech company using brain shuttle technology to develop RNA medicines for CNS diseases, today announced the close of a €32 million ($39 million) Series A financing to improve delivery of RNAi interference (RNAi) therape... |
| 15.12.2025 | EpilepsyGTx Secures $33M to Pioneer Single-Dose Gene Therapy for Refractory Epilepsy | EpilepsyGTx just raised $33 million. This Series A funding will fuel clinical trials. Their focus? A gene therapy for focal refractory epilepsy (FRE). FRE impacts millions globally. Current treatments often fail. EpilepsyGTx offers a potent... |
| 12.12.2025 | EpilepsyGTx Secures $33 Million Series A To Advance Single-Dose Gene Therapy For Focal Refractory Epilepsy | EpilepsyGTx, a biotechnology company focused on developing gene therapies for refractory epilepsy, has raised $33 million in a Series A financing to advance its lead program, EPY201, into first-in-human clinical trials. The funding will sup... |
| 10.12.2025 | EpilepsyGTx raises $33 million Series A to develop single dose gene therapy for focal refractory epilepsy | Investment from XGEN Venture, British Business Bank, and a global biopharmaceutical company will support first-in-human Phase 1/2a clinical trials for lead candidate EPY201 targeting focal refractory epilepsy (FRE) Future financings to adva... |
| 10.12.2025 | EpilepsyGTx Raises $33M in Series A Funding | EpilepsyGTx, a London, UK-based biotechnology company focused on research and development of gene therapies to treat refractory epilepsy, raised $33m in Series A financing. The round included investment from XGEN Venture, the British Busine... |
| 10.12.2025 | Gene therapy for severe epilepsy moves forward with EpilepsyGTx’s €28 million funding | EpilepsyGTx, a Cambridge-based BioTech startup focused on research and development of gene therapies to treat refractory epilepsy, today announced it has raised €28 million ($33 million) in Series A financing to advance its lead programme E... |
| 24.06.2024 | EpilepsyGTx announces a $10M fundraise to complete the CTA-enabling nonclinical package for lead program EPY201 | LONDON–(BUSINESS WIRE)–June 24, 2024– EpilepsyGTx, a biotechnology company focused on research and development of cutting-edge gene therapies to treat focal refractory epilepsy, today announced it has raised a total of $10 million in seed f... |
| 24.06.2024 | EpilepsyGTx Raises $10M in Seed Funding | EpilepsyGTx, a London, UK-based biotechnology company focused on research and development of gene therapies to treat focal refractory epilepsy, raised $10M in Seed funding. The round was led by UCL Technology Fund, with participation from H... |
Show more